ACP Journal Club. Meta-analysis: Atorvastatin reduces CV events and increases new-onset diabetes in patients with coronary disease.

Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus.

M e t h o d s Design: Randomized placebo-controlled trial (Collaborative Atorvastatin Diabetes Study [CARDS]). Allocation: Concealed.* Blinding: Blinded (clinicians, patients, pharmacists, data collectors, outcome assessors, monitoring committee, and data analysts).* Follow-up period: Median 3.9 years. Setting: 132 clinical centers in the United Kingdom and Ireland. Patients: 2838 patients 40 t...

Atorvastatin reduced stroke and CV events after recent stroke or TIA in patients with no known coronary heart disease.

M e t h o d s Design: Randomized placebo-controlled trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels [SPARCL] trial). Allocation: {Concealed}†.* Blinding: Blinded (clinicians, patients, data safety and monitoring committee, {data collectors, outcome assessors, and data analysts}†).* Follow-up period: Median 4.9 years (range 4.0 to 6.6 y). Setting: 205 centers in 27 countri...

Atorvastatin did not prevent cardiovascular events or death in patients with type 2 diabetes receiving hemodialysis.

A comparative study on the efficacy of Atorvastatin on change CRP, LDL by systematic review and meta-analysis

Background: Coronary artery disease today is a major contributor to mortality and morbidity from cardiovascular disease. The drug, interventional and surgical methods are used to treat coronary artery stenosis. Statins are the most commonly used drugs for stenosis and coronary artery disease. Low-density lipoprotein (LDL) The purpose of this study was to evaluate the effect of atorvastatin on L...

Atorvastatin reduced coronary and stroke events in patients with hypertension and without dyslipidemia.

I n r e s p o n s e : Regarding the subgroup analyses in ASCOT, as displayed in Figure 5 and Table 4 of the ASCOT-LLA paper (2), there were 7 subgroups in which a statistically significant beneficial effect of atorvastatin was not observed. However, as the authors noted and as was displayed visually in Figure 5, the proportional beneficial effect on 6 subgroups (diabetes, left ventricular hyper...